Reboot Rx

The Problem
Each year, 10 million people die of cancer. Cancer patients urgently need more affordable and effective treatment options. Yet developing one new drug can take over a decade and $1B, and even then it may only extend survival by a few months and cost over $100,000 annually. Around 40% of cancer patients in the U.S. exhaust their life savings within two years of diagnosis. There is a major opportunity to reduce the time and cost of creating new cancer treatments — while also prioritizing globally accessible therapies — through the repurposing of FDA-approved generic drugs. However, a market failure stands in the way: repurposing generic drugs is not financially rewarding for pharmaceutical companies, and the government does not fund late-stage drug development, so potential treatments do not reach patients. Reboot Rx is dedicated to fixing this market failure, giving generic drugs a new life in oncology — and extending the lives of oncology patients with inexpensive treatments.

The Solution
Reboot Rx envisions a future where cancer patients worldwide have access to effective, low-cost treatment options that help them live longer and better lives. Using their AI technology powered by machine learning and natural language processing, Reboot Rx accelerates the drug development process, identifying high-potential drug candidates for repurposing in weeks instead of years. Using this innovative approach, Reboot Rx scientists identified promising generic drugs for prostate cancer, which have already been tested through Phase II clinical trials. They are now validating their findings with real-world evidence using electronic medical record data and results from larger clinical trials by partnering with healthcare systems like the VA. Reboot Rx will drive the adoption of generic drugs into the standard of care, increasing access for patients everywhere.

Over the next three years, Reboot Rx will identify the most promising generic drugs for multiple other cancer types and work to introduce these drugs into the standard of care for all patients. Scaling Reboot Rx’s approach for the 10 most common cancers could yield 30 additional promising generic drugs for repurposing, with the potential to quickly expand treatment options for 9 million patients each year, including the most vulnerable in the U.S. who often can’t afford the co-pays related to the cancer treatments prescribed and so forego care.